Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial   entities : Tg therapeutics, inc.    save search
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2023-06-02 (Crawled : 13:20) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.67% H: 0.54% C: -3.77%
briumvi presentation sclerosis trials meeting therapeutics
TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2023-05-31 (Crawled : 11:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -0.27% H: 7.04% C: 4.76%
briumvi sclerosis trials meeting therapeutics
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting
Published: 2023-04-25 (Crawled : 14:20) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.09% H: 8.17% C: -1.19%
briumvi presentation sclerosis trials meeting therapeutics
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
Published: 2023-03-03 (Crawled : 14:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.95% H: 8.3% C: 7.18%
trials meeting therapeutics sclerosis
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2023-02-24 (Crawled : 13:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -2.49% H: 1.2% C: -2.12%
treatment trials research therapeutics presentation sclerosis multiple sclerosis
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2023-02-14 (Crawled : 16:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -1.9% H: 5.99% C: 5.32%
treatment trials research therapeutics sclerosis multiple sclerosis
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
Published: 2022-10-26 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -0.93% H: 11.07% C: 3.75%
treatment trials research therapeutics presentation sclerosis multiple sclerosis
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
Published: 2022-10-13 (Crawled : 12:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -5.1% H: 7.04% C: 5.93%
treatment trials research therapeutics sclerosis multiple sclerosis
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
Published: 2022-08-25 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 1.34% H: 2.77% C: 0.66%
trials therapeutics results
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -1.36% H: 2.53% C: 0.0%
trials therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2022-06-03 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 5.63% H: 11.62% C: 6.54%
trials therapeutics presentation sclerosis phase 3 multiple sclerosis
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.81% H: 5.31% C: 1.2%
trials therapeutics sclerosis phase 3 multiple sclerosis
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
Published: 2022-04-06 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -2.1% H: 3.71% C: 2.34%
trials therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
Published: 2022-04-04 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.4% H: 5.43% C: 5.34%
trials therapeutics sclerosis phase 3 multiple sclerosis
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
Published: 2022-03-04 (Crawled : 13:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -11.07% H: 0.0% C: 0.0%
america multiple sclerosis als trials trial therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2022-02-25 (Crawled : 13:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 10.03% H: 0.0% C: 0.0%
america multiple sclerosis treatment als trials research trial therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2022-02-15 (Crawled : 13:30) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 2.51% H: 8.21% C: 6.84%
america multiple sclerosis treatment als trials research trial therapeutics presentation sclerosis phase 3
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: -5.49% H: 2.43% C: -2.68%
ema trial therapeutics phase 3
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Published: 2021-09-29 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.7% H: 2.16% C: 0.9%
presentation multiple sclerosis treatment europe trials sclerosis phase 3 research trial
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
Published: 2021-06-18 (Crawled : 19:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
presentation multiple sclerosis europe sclerosis phase 3 trial
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance
EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services
NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services
INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.